Today Dr. Dipnarine Maharaj will be speaking to the Southeast Chapter of the Scleroderma Foundation in Boynton Beach Florida. Please see the information below:
Thursday Evening
October 3, 2013
at 6:00 pm - 7:00 pm
for a presentation
by
Dr. Dipnarine Maharaj M.D., MB, ChB, FRCP (Glasgow), FRCP (Edinburgh),
Dipnarine Maharaj is an American physician, author, clinical researcher and Founder & Medical Director of the South Florida Bone Marrow Stem Cell Transplant Institute and the Stem Cell Cryobank located in Boynton Beach Florida. The Institute is one of the few completely outpatient stem cell transplant facilities in the US. As an expert in stem cells, he has conducted research regarding adult stem cell therapies and their impact on the immune system in the treatment of cancers and other diseases. He has served as a professor at the University of Miami, Nova Southeastern University, and Florida Atlantic University.
Dr. Maharaj performs stem cell/bone marrow transplants for patients with leukemia and other cancers and blood disorders. More recently, he has been advocating collecting and storing healthy adult stem cells for future use as the number of approved diseases for treatment with adult stem cells grows. He is also developing clinical protocols using the individual’s own stem cells for the treatment of chronic diseases such as diabetes and neurodegenerative disorders such as strokes, Parkinson’s disease, Alzheimer’s disease, and cardiac diseases.
Maharaj is the author of more than 80 published research papers and abstracts on bone marrow and stem cell transplantation for blood disorders, cancers, Parkinson’s disease, diabetes, and other inflammatory diseases. He has also developed a new protocol for Parkinson’s disease patients, for which he was awarded a United States Patent. Currently he is running an FDA approved Phase I/Phase II Clinical Trial for solid tumor cancers. He was profiled by Suzanne Somers for his work with cancer in her book Bombshell: Explosive Medical Secrets that will Redefine Aging (2012) where she categorized him as “America’s Leading Expert on Stem Cell Technologies”. In association with A4M (American Academy of Anti-Aging Medicine) he created the Stem Cell Fellowship, an educational certification program for physicians interested in adult stem cell patient treatment.
Dipnarine Maharaj was born at Palmyra in the suburbs of San Fernando, Trinidad and raised in Scotland. He received his medical degree in 1978 from the University of Glasgow Medical School, Scotland. He completed his internship and residency in Internal Medicine and Hematology at the University's Royal Infirmary. He completed a three-year fellowship in Hematology, Oncology, and Bone Marrow Transplantation.
Following his training, Dr. Maharaj worked with Alan Burnett, M.D., chairman of the United Kingdom Medical Research Council's Acute Leukemia trials. Together, they helped develop the first Scottish Bone Marrow/Stem Cell Transplant Program and they were one of the first centers to publish their data on the use of autologous bone marrow transplantation for acute myeloid leukemia.
Dr. Maharaj moved to the United States in 1990 to join the University of Miami’s (UM) bone marrow transplant team which was led by Dr. John Byrnes, who had trained with Dr. George Santos at Johns Hopkins Bone Marrow Transplant Center. Dr. Byrnes and Dr. Maharaj performed the first autologous bone marrow transplant at the University of Miami in 1991.
Following a three-year tenure at UM, Dr. Maharaj began a totally outpatient Bone Marrow/Stem Cell Transplant Institute at Florida Medical Center in 1995. In 1997, he aligned with Bethesda Health Care System in Boynton Beach continuing as medical director of the Bone Marrow/Stem Cell Transplant Institute at Bethesda, developing the outpatient program, and eventutally took the Institute independent by 2001. The Institute is FDA registered, Joint Commission Accredited (JCAHO), and accredited by the AABB (American Association of Blood Banks). It is an affiliate of the H. Lee Moffitt Cancer.
During his career in the United States, Dr. Maharaj has conducted research as the Principal Investigator for organizations & corporations such as the American Cancer Society, Immunex, Genentech, Amgen, Biomira, and Genzyme. He currently is on staff at Bethesda Memorial Hospital in Boynton Beach, FL where he was awarded Physician of the Month in April 2010.
1974: British Council Scholarship in Medicine 1976: Certificate of Merit in Internal Medicine, Surgery, Hematology 1977: Macleod Medal and Prize in Medicine and Surgery 1986: Traveling Fellowship, Royal College of Physicians of Edinburgh 1990: Myre Sim Traveling Fellowship, Royal College of Physicians of Edinburgh 2000-2009: Culpepper Foundation Grant 2007: Coley-Bankhead Grant
Dr. Maharaj is one of the inventors of the Parkinson’s treatment that was awarded a U.S. patent in May 2010 (US 7723302). The invention relates to the discovery that in an animal model of Parkinson's disease (PD), administration of granulocyte colony-stimulating factor (G-CSF) to rodents having 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD restored the function of dopamine neurons. In these animals, G-CSF treatment increased the number of dopamine neurons in the substantia nigra (SN), G-CSF treatment partially restored the nigrostriatal pathway, and G-CSF restored the function of dopamine to the level before MPTP treatment. The invention also relates to the discovery that treatment of a human patient with corticobasilar ganglionic degeneration, a rare progressive neurological disorder characterized by Parkinsonism and coritcal dysfunction, with G-CSF resulted in a significant improvement in the patient's Unified Parkinson's Disease Rating Scale evaluations as well as measures of activity of daily living. The invention further relates to the discovery that G-CSF treatment of a patient who had suffered an acute stroke resulted in a significant improvement in neurological function, the patient having minimal observable disability seven years later. The above method can be used to treat Alzheimer’s disease, stroke, and spinal cord injuries as well.
The South Florida Bone Marrow/Stem Cell Transplant Institute, with Dr. Dipnarine Maharaj M.D. as the principal investigator, is running an FDA approved IND (Investigational New Drug) Phase I/Phase II clinical trial (Clinical trial 08001-BMSCTI) studying a novel cancer therapy using transfusions of white blood cells from healthy donors. It will study the ability to transfer naturally occurring cancer-killing activity (CKA) in the granulocytes of selected donors into the body of a cancer patient.
The new cancer therapy was developed from the research results from Dr. Zheng Cui of Wake Forest University and Dr. Cui’s studies of natural cancer resistance in a unique strain of lab mouse (SR/CR mice) and in some healthy humans.
In 2010, Dr. Maharaj received a grant from the Life Extension Foundation for the clinical trial, which provided initial funding to start the study. Dr. Maharaj notes that the critical research could not take place without the help from the Life Extension Foundation.
The Life Extension Foundation does not have any financial interest in the outcome of the research project. They simply want to discover the means to possibly help cure cancer. The foundation wants to be able to recommend a validated cure for cancer to the millions of supporters following the organization.
Suzanne Somers: Bombshell Explosive Medical Secrets that will Redefine Aging[edit source | editbeta]
At the request of noted futurist and inventor Ray Kurzweil, Suzanne Somers dedicated a chapter of her book Bombshell: Explosive Medical Secrets That Will Redefine Aging (2012) to Dr. Dipnarine Maharaj and his advancements in stem cell research. She acknowledged the breakthroughs he has made in Parkinson’s disease and cancer treatment. Somers also interviewed Dr. Maharaj on air on her talk show, Suzanne Somers Breaking Through, about his clinical trial and voiced personal support for the study. Somers even went so far as to say that she believes Dr. Maharaj possesses the ability to one day find a cure for cancer and has discussed his research on the NBC Today show with Savannah Guthrie.
Based on the work of Dr. Zheng Cui PhD, Dr. Dipnarine Maharaj MD, FACP, Medical Director of the South Florida Bone Marrow/Stem Cell Transplant Institute...
Jul 16, 2013 - Dr. Dipnarine Maharaj is the Medical Director and founder of the South Florida Bone Marrow/Stem Cell Transplant Institute, one of the few ...
Internationally Recognized Stem Cell Transplant Physician & Research in the fight against Cancer, Parkinson's Disease, Leukemia, Alzheimer's Disease, ...
View Dipnarine Maharaj's professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like Dipnarine Maharaj...
Dr. Dipnarine Maharaj's Message: The ability of stem cells to repair the cells and tissues of the body is an observation that I have made in the many years that I ...
Miami/Fort Lauderdale Area - electronics technician at dmelectronics
View dipnarine maharaj's professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like dipnarine maharaj...
Dr. Dipnarine Maharaj wrote 2 days ago : The Role of Stem Cells in Regenerative Medicine and ... Stem Cells and Aging Written By Dr. Dipnarine Maharaj M.D..
The key to the body is the
immune system.It is through the immune
system that the body is able to ward off intruders and eliminate dangerous cell
mutations.
However, the body is filled
with inflammation.As inflammation grows
within our bodies, our immune system must focus more of its time and effort to
healing inflammation rather than killing off disease.
The future of medicine will
be to assist the immune system and to replace damaged cells with new healthy
ones.
It is through this knowledge
that we seek out the latest techniques in stem cell and regenerative
medicine.By activating the stem cells
either within the body or receiving them from another donor we can begin to
increase our immune power to bolster our immune defenses against many diseases.
Even further stem cells have
the ability to repair many different types of cells and have proven their
regenerative properties.By studying and
researching these properties, we hope to develop and implement protocols that
will greatly improve the treatment of cancer, diabetes, Parkinson’s disease,
and Traumatic Brain Injury (TBI).
The Stem Cell Cancer &
Regenerative Medicine Research Inc. foundation (“The Foundation”) has pledged
its entire existence towards the research and education of adult stem cells for
the purposes of treating cancer, neurodegenerative diseases, and chronic
illnesses.
We feel through our work in
stem cells, along with a commitment to excellence and patient care that we will
be able influence many fields of medicine and patient treatment as we know it.
25.8 million children
and adults in the United States—8.3% of the population
This picture caption uses the Caption 2 paragraph style
and is inside a text box so that you can move it easily as needed to
accompany a photo.
Diagnosed: 18.8 million
people
Undiagnosed: 7.0 million people
Prediabetes: 79 million people*
New Cases: 1.9 million new cases of diabetes are diagnosed in people aged 20
years and older in 2010.
* In contrast to the 2007 National Diabetes Fact Sheet, which used fasting
glucose data to estimate undiagnosed diabetes and prediabetes, the 2011
National Diabetes Fact Sheet uses both fasting glucose and A1C levels to derive
estimates for undiagnosed diabetes and prediabetes. These tests were chosen
because they are most frequently used in clinical practice.
Under 20
years of age
* 215,000, or 0.26% of all people in this age group have
diabetes
* About 1 in every 400 children and adolescents has type 1
diabetes
Age 20 years
or older
* 25.6 million, or 11.3% of all people in this age group
have diabetes
Age 65 years
or older * 10.9
million, or 26.9% of all people in this age group have diabetes
Men * 13.0
million, or 11.8% of all men aged 20 years or older have diabetes
Women * 12.6
million, or 10.8% of all women aged 20 years or older have diabetes
Race and
ethnic differences in prevalence of diagnosed diabetes
After adjusting for population age differences, 2007-2009 national survey data
for people diagnosed with diabetes, aged 20 years or older include the
following prevalence by race/ethnicity:
* 7.1% of non-Hispanic whites
* 8.4% of Asian Americans
* 12.6% of non-Hispanic blacks
* 11.8% of Hispanics
Among
Hispanics rates were:
* 7.6% for Cubans
* 13.3% for Mexican Americans
* 13.8% for Puerto Ricans.
Morbidity and Mortality
* In 2007, diabetes was listed as the underlying cause on
71,382 death certificates and was listed as a contributing factor on an
additional 160,022 death certificates. This means that diabetes contributed to
a total of 231,404 deaths.
Complications
Heart disease and stroke
* In 2004, heart disease was noted on 68% of
diabetes-related death certificates among people aged 65 years or older.
* In 2004, stroke was noted on 16% of diabetes-related death
certificates among people aged 65 years or older.
* Adults with diabetes have heart disease death rates about
2 to 4 times higher than adults without diabetes.
* The risk for stroke is 2 to 4 times higher among people
with diabetes.
High blood pressure
* In 2005-2008, of adults aged 20 years or older with
self-reported diabetes, 67% had blood pressure greater than or equal to 140/90
mmHg or used prescription medications for hypertension.
Blindness
* Diabetes is the leading cause of new cases of blindness
among adults aged 20–74 years.
* In 2005-2008, 4.2 million (28.5%) people with diabetes
aged 40 years or older had diabetic retinopathy, and of these, almost 0.7
million (4.4% of those with diabetes) had advanced diabetic retinopathy that
could lead to severe vision loss.
Kidney disease
* Diabetes is the #1 cause of kidney failure, accounting for
44% of new cases in 2008.
* In 2008, 48,374 people with diabetes began treatment for
end-stage kidney disease in the United States.
* In 2008, a total of 202,290 people with end-stage kidney
disease due to diabetes were living on chronic dialysis or with a kidney
transplant in the United States.
Nervous system disease (Neuropathy)
* About 60% to 70% of people with diabetes have mild to
severe forms of nervous system damage.
Amputation
* More than 60% of nontraumatic lower-limb amputations occur
in diabetics.
*
In 2006, about 65,700 nontraumatic lower-limb amputations were performed in
people with diabetes.
Cost of Diabetes:
* $174 billion: Total costs of diagnosed diabetes in the
United States in 2007
* $116 billion for direct medical costs
* $58 billion for indirect costs (disability, work loss,
premature mortality)
After adjusting for population age and sex differences, average medical
expenditures among people with diagnosed diabetes were 2.3 times higher than
what expenditures would be in the absence of diabetes.
Estimates related to the cost of diabetes have been calculated by the American
Diabetes Association are as follows:
Factoring in the additional costs of undiagnosed diabetes, gestational diabetes
brings the total diabetes to $218 billion.
